ELTX
HEALTHCAREElicio Therapeutics Inc
$10.45-0.14 (-1.32%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ELTX Today?
No stock-specific AI insight has been generated for ELTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.15$14.93
$10.45
Fundamentals
Market Cap$195M
P/E Ratio—
EPS$-2.58
Dividend Yield—
Dividend / Share—
ROE-600.1%
Profit Margin—
Debt / Equity—
Trading
Volume97K
Avg Volume (10D)—
Shares Outstanding18.7M
ELTX News
20 articles- Elicio Therapeutics to Present at the Bank of America Healthcare ConferenceYahoo Finance·Apr 30, 2026
- Elicio Therapeutics Reports Inducement GrantsYahoo Finance·Apr 16, 2026
- Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?Yahoo Finance·Mar 20, 2026
- Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should KnowYahoo Finance·Mar 18, 2026
- Elicio Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 12, 2026
- Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdatesYahoo Finance·Mar 12, 2026
- Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 25, 2026
- While insiders own 33% of Elicio Therapeutics, Inc. (NASDAQ:ELTX), individual investors are its largest shareholders with 55% ownershipYahoo Finance·Jan 28, 2026
- Elicio Therapeutics (ELTX) Upgraded to Buy: Here's WhyYahoo Finance·Dec 11, 2025
- Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P TrialYahoo Finance·Dec 11, 2025
- Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsightYahoo Finance·Dec 10, 2025
- Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology OfficerYahoo Finance·Nov 19, 2025
- Elicio Therapeutics: Q3 Earnings SnapshotYahoo Finance·Nov 13, 2025
- Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesYahoo Finance·Nov 13, 2025
- KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsightYahoo Finance·Nov 12, 2025
- Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITCYahoo Finance·Nov 7, 2025
- Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P TrialYahoo Finance·Oct 27, 2025
- Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal AdenocarcinomaYahoo Finance·Sep 29, 2025
- Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P TrialYahoo Finance·Sep 17, 2025
- Elicio’s peptide cancer vaccine shows survival benefit in Phase I trialClinicaltrialsarena·Aug 13, 2025
All 20 articles loaded
Price Data
Open$10.69
Previous Close$10.59
Day High$10.69
Day Low$10.29
52 Week High$14.93
52 Week Low$5.15
52-Week Range
$5.15$14.93
$10.45
Fundamentals
Market Cap$195M
P/E Ratio—
EPS$-2.58
Dividend Yield—
Dividend / Share—
ROE-600.1%
Profit Margin—
Debt / Equity—
Trading
Volume97K
Avg Volume (10D)—
Shares Outstanding18.7M
About Elicio Therapeutics Inc
Elicio Therapeutics Inc. (ELTX) is an innovative clinical-stage biotechnology firm at the forefront of developing transformative immunotherapy solutions for cancer treatment. The company's proprietary Amphiphilic TLR9 Agonist, Eli-002, is designed to stimulate strong immune responses against various cancer types, aiming to significantly improve treatment outcomes for patients. With a strategic emphasis on personalized cancer vaccines and cutting-edge immunotherapeutic strategies, Elicio is well-positioned to address substantial unmet medical needs within oncology, actively advancing its clinical trials to redefine cancer care.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—